Drug utilization research in the area of cancer drugs

Tanja Mueller; Mikael Hoffmann

doi:10.1002/9781119911685.ch36

Drug utilization research in the area of cancer drugs

Tanja Mueller, Mikael Hoffmann

Strathclyde Institute Of Pharmacy And Biomedical Sciences

Research output: Chapter in Book/Report/Conference proceeding › Chapter

Abstract

The world-wide impact of cancer on life expectancy, quality of life, and need for healthcare interventions together explain the research interest and rapid development of new therapeutic alternatives for the treatment of cancer. This chapter presents the examples for the main types of systemic anti-cancer therapy (SACT) currently in use. In Europe most cancer drugs are authorised by the European Medicines Agency through centralised marketing authorisation applications. Studying utilization of cancer drugs introduces additional and severe challenges compared to many other therapeutic areas. The concept of defined daily doses needs to be handled carefully for cancer drugs. Due to the lack of robust ways of measuring the amount of SACT used and the importance placed on the expenditures on cancer drugs, international comparisons in particular tend to focus on total cost of the drugs instead of amount distributed.

Original language	English
Title of host publication	Drug Utilization Research
Subtitle of host publication	Methods and Applications
Editors	Monique Elseviers, Björn Wettermark, Ria Benkő, Marion Bennie, Katarina Gvozdanović, Mikael Hoffmann, Irina Iaru, Verica Ivanovska, Sean MacBride-Stewart, Tanja Mueller, Elisabetta Poluzzi, Lisa Pont, Hege Salvesen Blix, Gabriel Sanfélix-Gimeno, Gisbert Selke, Katja Taxis, Ana Tomas Petrović, Indrė Trečiokienė, Sabine Vogler
Place of Publication	Hoboken, NJ
Publisher	Wiley-Blackwell
Chapter	3.4.6
Pages	373-380
Number of pages	8
Edition	2nd
ISBN (Electronic)	9781119911685
ISBN (Print)	9781119911654
DOIs	https://doi.org/10.1002/9781119911685.ch36
Publication status	Published - 9 Sept 2024

Keywords

cancer drugs
defined daily doses
drug utilisation research
systemic anti-cancer therapy
therapeutic areas

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1002/9781119911685.ch36

Mueller-Hoffmann-Wiley-2024-Drug-utilization-research-in-the-area-of-cancer-drugsAccepted author manuscript, 1.37 MBLicence: Strath_1

Cite this

Mueller, T., & Hoffmann, M. (2024). Drug utilization research in the area of cancer drugs. In M. Elseviers, B. Wettermark, R. Benkő, M. Bennie, K. Gvozdanović, M. Hoffmann, I. Iaru, V. Ivanovska, S. MacBride-Stewart, T. Mueller, E. Poluzzi, L. Pont, H. Salvesen Blix, G. Sanfélix-Gimeno, G. Selke, K. Taxis, A. Tomas Petrović, I. Trečiokienė, & S. Vogler (Eds.), Drug Utilization Research: Methods and Applications (2nd ed., pp. 373-380). Wiley-Blackwell. https://doi.org/10.1002/9781119911685.ch36

Mueller, Tanja ; Hoffmann, Mikael. / Drug utilization research in the area of cancer drugs. Drug Utilization Research: Methods and Applications. editor / Monique Elseviers ; Björn Wettermark ; Ria Benkő ; Marion Bennie ; Katarina Gvozdanović ; Mikael Hoffmann ; Irina Iaru ; Verica Ivanovska ; Sean MacBride-Stewart ; Tanja Mueller ; Elisabetta Poluzzi ; Lisa Pont ; Hege Salvesen Blix ; Gabriel Sanfélix-Gimeno ; Gisbert Selke ; Katja Taxis ; Ana Tomas Petrović ; Indrė Trečiokienė ; Sabine Vogler. 2nd. ed. Hoboken, NJ : Wiley-Blackwell, 2024. pp. 373-380

@inbook{ac1b41bf7f13424aac32f51e88a8c1e4,

title = "Drug utilization research in the area of cancer drugs",

abstract = "The world-wide impact of cancer on life expectancy, quality of life, and need for healthcare interventions together explain the research interest and rapid development of new therapeutic alternatives for the treatment of cancer. This chapter presents the examples for the main types of systemic anti-cancer therapy (SACT) currently in use. In Europe most cancer drugs are authorised by the European Medicines Agency through centralised marketing authorisation applications. Studying utilization of cancer drugs introduces additional and severe challenges compared to many other therapeutic areas. The concept of defined daily doses needs to be handled carefully for cancer drugs. Due to the lack of robust ways of measuring the amount of SACT used and the importance placed on the expenditures on cancer drugs, international comparisons in particular tend to focus on total cost of the drugs instead of amount distributed.",

keywords = "cancer drugs, defined daily doses, drug utilisation research, systemic anti-cancer therapy, therapeutic areas",

author = "Tanja Mueller and Mikael Hoffmann",

note = "Copyright {\textcopyright} 2024 John Wiley & Sons, Ltd",

year = "2024",

month = sep,

day = "9",

doi = "10.1002/9781119911685.ch36",

language = "English",

isbn = "9781119911654",

pages = "373--380",

editor = "Monique Elseviers and Bj{\"o}rn Wettermark and Ria Benk{\H o} and Marion Bennie and Katarina Gvozdanovi{\'c} and Mikael Hoffmann and Irina Iaru and Verica Ivanovska and Sean MacBride-Stewart and Mueller, {Tanja } and Elisabetta Poluzzi and Lisa Pont and {Salvesen Blix}, Hege and Gabriel Sanf{\'e}lix-Gimeno and Gisbert Selke and Katja Taxis and {Tomas Petrovi{\'c}}, Ana and Indrė Tre{\v c}iokienė and Sabine Vogler",

booktitle = "Drug Utilization Research",

publisher = "Wiley-Blackwell",

edition = "2nd",

}

Mueller, T & Hoffmann, M 2024, Drug utilization research in the area of cancer drugs. in M Elseviers, B Wettermark, R Benkő, M Bennie, K Gvozdanović, M Hoffmann, I Iaru, V Ivanovska, S MacBride-Stewart, T Mueller, E Poluzzi, L Pont, H Salvesen Blix, G Sanfélix-Gimeno, G Selke, K Taxis, A Tomas Petrović, I Trečiokienė & S Vogler (eds), Drug Utilization Research: Methods and Applications. 2nd edn, Wiley-Blackwell, Hoboken, NJ, pp. 373-380. https://doi.org/10.1002/9781119911685.ch36

Drug utilization research in the area of cancer drugs. / Mueller, Tanja; Hoffmann, Mikael.
Drug Utilization Research: Methods and Applications. ed. / Monique Elseviers; Björn Wettermark; Ria Benkő; Marion Bennie; Katarina Gvozdanović; Mikael Hoffmann; Irina Iaru; Verica Ivanovska; Sean MacBride-Stewart; Tanja Mueller; Elisabetta Poluzzi; Lisa Pont; Hege Salvesen Blix; Gabriel Sanfélix-Gimeno; Gisbert Selke; Katja Taxis; Ana Tomas Petrović; Indrė Trečiokienė; Sabine Vogler. 2nd. ed. Hoboken, NJ: Wiley-Blackwell, 2024. p. 373-380.

Research output: Chapter in Book/Report/Conference proceeding › Chapter

TY - CHAP

T1 - Drug utilization research in the area of cancer drugs

AU - Mueller, Tanja

AU - Hoffmann, Mikael

PY - 2024/9/9

Y1 - 2024/9/9

N2 - The world-wide impact of cancer on life expectancy, quality of life, and need for healthcare interventions together explain the research interest and rapid development of new therapeutic alternatives for the treatment of cancer. This chapter presents the examples for the main types of systemic anti-cancer therapy (SACT) currently in use. In Europe most cancer drugs are authorised by the European Medicines Agency through centralised marketing authorisation applications. Studying utilization of cancer drugs introduces additional and severe challenges compared to many other therapeutic areas. The concept of defined daily doses needs to be handled carefully for cancer drugs. Due to the lack of robust ways of measuring the amount of SACT used and the importance placed on the expenditures on cancer drugs, international comparisons in particular tend to focus on total cost of the drugs instead of amount distributed.

AB - The world-wide impact of cancer on life expectancy, quality of life, and need for healthcare interventions together explain the research interest and rapid development of new therapeutic alternatives for the treatment of cancer. This chapter presents the examples for the main types of systemic anti-cancer therapy (SACT) currently in use. In Europe most cancer drugs are authorised by the European Medicines Agency through centralised marketing authorisation applications. Studying utilization of cancer drugs introduces additional and severe challenges compared to many other therapeutic areas. The concept of defined daily doses needs to be handled carefully for cancer drugs. Due to the lack of robust ways of measuring the amount of SACT used and the importance placed on the expenditures on cancer drugs, international comparisons in particular tend to focus on total cost of the drugs instead of amount distributed.

KW - cancer drugs

KW - defined daily doses

KW - drug utilisation research

KW - systemic anti-cancer therapy

KW - therapeutic areas

U2 - 10.1002/9781119911685.ch36

DO - 10.1002/9781119911685.ch36

M3 - Chapter

SN - 9781119911654

SP - 373

EP - 380

BT - Drug Utilization Research

A2 - Elseviers, Monique

A2 - Wettermark, Björn

A2 - Benkő, Ria

A2 - Bennie, Marion

A2 - Gvozdanović, Katarina

A2 - Hoffmann, Mikael

A2 - Iaru, Irina

A2 - Ivanovska, Verica

A2 - MacBride-Stewart, Sean

A2 - Mueller, Tanja

A2 - Poluzzi, Elisabetta

A2 - Pont, Lisa

A2 - Salvesen Blix, Hege

A2 - Sanfélix-Gimeno, Gabriel

A2 - Selke, Gisbert

A2 - Taxis, Katja

A2 - Tomas Petrović, Ana

A2 - Trečiokienė, Indrė

A2 - Vogler, Sabine

PB - Wiley-Blackwell

CY - Hoboken, NJ

ER -

Mueller T, Hoffmann M. Drug utilization research in the area of cancer drugs. In Elseviers M, Wettermark B, Benkő R, Bennie M, Gvozdanović K, Hoffmann M, Iaru I, Ivanovska V, MacBride-Stewart S, Mueller T, Poluzzi E, Pont L, Salvesen Blix H, Sanfélix-Gimeno G, Selke G, Taxis K, Tomas Petrović A, Trečiokienė I, Vogler S, editors, Drug Utilization Research: Methods and Applications. 2nd ed. Hoboken, NJ: Wiley-Blackwell. 2024. p. 373-380 doi: 10.1002/9781119911685.ch36

Drug utilization research in the area of cancer drugs

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this